Exome Asset Management’s Lipocine LPCN Stock Holding History

Exome Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$486K	Buy	+60,861	New	+$530K	0.25%	53

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Seven Fleet Capital Management Mountain View, California $318M AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Exome Asset Management's LPCN Position: Q1 2026 in Review

Exome Asset Management opened a new position in Lipocine (LPCN) in Q1 2026: 60,861 shares worth $486K. The stake represents 0.25% of the portfolio and ranks #53 among its holdings.

47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

Exome Asset Management held 60,861 shares of Lipocine worth $486K as of Q1 2026.
Lipocine was a new Exome Asset Management position in Q1 2026.
Lipocine made up 0.25% of Exome Asset Management's portfolio in Q1 2026, its #53 holding.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.